Used in targeted cancer therapies, particularly for tumors with c-Met receptor overexpression or dysregulation, such as non-small cell lung cancer, hepatocellular carcinoma, and gastric cancers. This antibody blocks hepatocyte growth factor (HGF)-mediated signaling through the c-Met pathway, inhibiting tumor cell proliferation, survival, migration, and invasion. It is employed in research and therapeutic development to study metastasis and angiogenesis, and serves as a reference in the design of biosimilars or novel anti-Met antibodies. Its high specificity makes it valuable in diagnostic assays and preclinical testing of combination therapies involving c-Met inhibition.